

January 31, 2012

The Honorable Vicki Schmidt, Chairperson  
Senate Committee on Public Health and Welfare  
Statehouse, Room 552-S  
Topeka, Kansas 66612

Dear Senator Schmidt:

**SUBJECT:** Fiscal Note for SB 325 by Senate Committee on Public Health and Welfare

In accordance with KSA 75-3715a, the following fiscal note concerning SB 325 is respectfully submitted to your committee.

SB 325 would amend the Controlled Substances Act. The bill would add the drug, *carisoprodol* to schedule IV and the drug, *ezogabine* to schedule V of the controlled substances lists. The Board of Pharmacy indicates that the United States Drug Enforcement Administration maintains a list of controlled substances classifying illicit drugs and makes amendments each year after reviewing a drug's pharmacology, chemistry, trafficking, actual abuse, pattern of abuse, and relative potential for abuse. Since the Board is required to follow all federal laws and these two drugs are currently controlled by the federal government, the Board has already been treating them as if they were controlled substances. This bill revises the controlled substances lists in the State of Kansas to match federal law.

The Board of Pharmacy indicates that SB 325 would have no fiscal effect on its operations. The Kansas Sentencing Commission has indicated that the bill would affect agency expenditures, but has not yet provided an estimate. Once information is provided, a revised fiscal note will be submitted.

Sincerely,



Steven J. Anderson, CPA, MBA  
Director of the Budget

cc: Debra Billingsley, Pharmacy  
Scott Schultz, Sentencing Commission